Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51

被引:41
|
作者
Eder, Susanne [2 ]
Dubischar-Kastner, Katrin [2 ]
Firbas, Christa [1 ]
Jelinek, Tomas [4 ]
Jilma, Bernd [1 ]
Kaltenboeck, Astrid [2 ]
Knappik, Michael [4 ]
Kollaritsch, Herwig [3 ]
Kundi, Michael [5 ]
Paulke-Korinek, Maria [3 ]
Schuller, Elisabeth [2 ]
Klade, Christoph S. [2 ]
机构
[1] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria
[2] Intercell AG, A-1030 Vienna, Austria
[3] Med Univ Vienna, Dept Specif Prophylaxis & Trop Med, A-1090 Vienna, Austria
[4] Ctr Travel & Trop Med, Berlin, Germany
[5] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, A-1090 Vienna, Austria
关键词
Japanese Encephalitis virus; Vaccination; Phase III clinical trial; Ixiaro; Jespect; TICK-BORNE ENCEPHALITIS; CONTROLLED PHASE-3; ANTIBODY-RESPONSE; IMMUNOGENICITY; SAFETY; IMMUNIZATION; SINGLE; VIRUS; TRIAL; PERSISTENCE;
D O I
10.1016/j.vaccine.2011.01.058
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: IXIARO (IC51), a recently approved inactivated Japanese Encephalitis vaccine, is immunogenic and safe in a 0/28 days primary immunization schedule. Neutralizing antibody titers decline with time and booster doses are likely needed to enhance persistence of immunity. Objectives: To assess the effect of a booster dose on neutralizing JE antibody titers for up to 12 months after boostering. Methods: In this phase III trial, 198 subjects, who had received primary immunization in a preceding randomized trial, were boosted with IXIARO 15 months after the primary immunization. Neutralizing antibody titers were assessed by plaque-reduction neutralisation test, PRNT. Results: Prior to the booster dose, 69.2% (137/198) of subjects had PRNT50 titers >= 1:10. One month after the booster, the rate of subjects with PRNT50 >= 1:10 (recognized as a protective titer) was 100%. This rate remained high at 98.5% at 6 and 12 months; GMTs were 22.5 before the booster and 900.487 and 361 at 1, 6 and 12 months after the booster, respectively. Conclusion: A booster dose of IXIARO at 15 months after primary immunization was highly immunogenic with GMTs >5-fold higher than those seen immediately after primary immunization, and remained at high levels for at least 12 months after the booster. NCT00595309. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2607 / 2612
页数:6
相关论文
共 50 条
  • [1] Long term immunogenicity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51
    Dubischar-Kastner, K. L.
    Eder, S.
    Jelinek, T.
    Jilma, B.
    Kaltenboeck, A.
    Kollaritsch, H.
    Schuller, E.
    Klade, C.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E449 - E449
  • [2] Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51
    Dubischar-Kastner, Katrin
    Eder, Susanne
    Buerger, Vera
    Gartner-Woelfl, Gabriele
    Kaltenboeck, Astrid
    Schuller, Elisabeth
    Tauber, Erich
    Klade, Christoph
    [J]. VACCINE, 2010, 28 (32) : 5197 - 5202
  • [3] LONG-TERM IMMUNITY FOLLOWING VACCINATION WITH THE INACTIVATED JAPANESE ENCEPHALITIS VACCINE IXIARO®, IC51, AND IMMUNE RESPONSE TO A BOOSTER DOSE
    Dubischar-Kastner, Katrin L.
    Eder, Susanne
    Kaltenboeck, Astrid
    Klade, Christoph
    Woelfl, Gabriele
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 81 (05): : 325 - 325
  • [4] IC51 Japanese Encephalitis Vaccine
    Jelinek, T.
    Kaltenboeck, A.
    [J]. DRUGS OF THE FUTURE, 2009, 34 (06) : 458 - 467
  • [5] IC51 Japanese Encephalitis vaccine
    Kollaritsch, Herwig
    Paulke-Korinek, Maria
    Dubischar-Kastner, Katrin
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (07) : 921 - 931
  • [6] IC51: a new investigational Japanese encephalitis vaccine
    Klade, Christoph S.
    [J]. EXPERT REVIEW OF VACCINES, 2008, 7 (08) : 1139 - 1140
  • [7] Japanese Encephalitis Vaccine (Inactivated, Adsorbed) [IXIARO®]
    Sean T. Duggan
    Greg L. Plosker
    [J]. Drugs, 2009, 69 : 115 - 122
  • [8] Japanese Encephalitis Vaccine (Inactivated, Adsorbed) [IXIARO®]
    Duggan, Sean T.
    Plosker, Greg L.
    [J]. DRUGS, 2009, 69 (01) : 115 - 122
  • [9] Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up
    Dubischar-Kastner, Katrin
    Kaltenboeck, Astrid
    Klingler, Anton
    Jilma, Bernd
    Schuller, Elisabeth
    [J]. VACCINE, 2010, 28 (39) : 6463 - 6469
  • [10] FIRST CLINICAL TRIAL OF A VERO CELL DERIVED, INACTIVATED JAPANESE ENCEPHALITIS (JE) VACCINE IC51 IN PEDIATRIC POPULATION
    Schuller, Elisabeth
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 246 - 246